1. Home
  2. MYFW vs ALLO Comparison

MYFW vs ALLO Comparison

Compare MYFW & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MYFW

First Western Financial Inc.

HOLD

Current Price

$26.43

Market Cap

255.0M

Sector

Finance

ML Signal

HOLD

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$1.71

Market Cap

252.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MYFW
ALLO
Founded
2002
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
255.0M
252.9M
IPO Year
2018
2018

Fundamental Metrics

Financial Performance
Metric
MYFW
ALLO
Price
$26.43
$1.71
Analyst Decision
Buy
Strong Buy
Analyst Count
2
12
Target Price
$24.25
$8.27
AVG Volume (30 Days)
31.2K
3.4M
Earning Date
01-22-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
391.62
N/A
EPS
1.28
N/A
Revenue
$95,514,000.00
N/A
Revenue This Year
$15.96
N/A
Revenue Next Year
$13.77
$100.00
P/E Ratio
$20.65
N/A
Revenue Growth
19.92
N/A
52 Week Low
$17.10
$0.86
52 Week High
$28.00
$3.78

Technical Indicators

Market Signals
Indicator
MYFW
ALLO
Relative Strength Index (RSI) 62.88 70.82
Support Level $25.82 $1.30
Resistance Level $27.15 $1.54
Average True Range (ATR) 0.70 0.10
MACD -0.05 0.02
Stochastic Oscillator 43.94 75.21

Price Performance

Historical Comparison
MYFW
ALLO

About MYFW First Western Financial Inc.

First Western Financial Inc is a financial holding company that provides a fully integrated suite of wealth management services on its private trust bank platform, which includes a comprehensive selection of deposit, loan, trust, wealth planning, and investment management products and services. The company has two operating segments; The Wealth Management segment consists of operations relative to the Company's fully integrated wealth management products and services, and The Mortgage segment consists of operations relative to the Company's residential mortgage service offerings. The bank derives its majority revenue from the wealth management segment.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: